Inhibrx | Investors

Recent News

Jun 15, 2026

Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma

No filing review issues identified by FDA with PDUFA goal date set for April 14, 2027 If Approved, Ozekibart Would Be the First and Only FDA-Approved Treatment for Unresectable or Metastatic...

May 14, 2026

Inhibrx Reports First Quarter 2026 Financial Results

Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the first quarter of 2026. The biopharmaceutical company has two programs in ongoing...

May 11, 2026

Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy

Interim analyses show INBRX-106 + pembrolizumab achieved a 44.0% confirmed Objective Response Rate (cORR): In the preliminary confirmed response-evaluable population, the INBRX-106 + pembrolizumab...

May 8, 2026

Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC

Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced...

View All Releases »

Events & Presentations

2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Saturday, May 30, 2026

Title: The tetravalent death receptor 5 (DR5) agonist ozekibart (INBRX-109) in conventional chondrosarcoma (CS): Secondary efficacy endpoints from the randomized, registrational, phase 2 ChonDRAgon study.
Lead Author: Hans Gelderblom
Abstract: 11504
Oral presentation: Saturday, May 30, 2026 (Session time: 4:12 PM – 4:24 PM CDT)

Title: Phase 1 study of the tetravalent death receptor 5 agonist ozekibart (INBRX-109) combined with chemotherapy in locally advanced or metastatic, unresectable colorectal adenocarcinoma (CRC).
Lead Author: Hazel Lote
Abstract: 3533
Poster presentation: Saturday, May 30, 2026 (Session time: 9:00 AM – 12:00 PM CDT)

Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC

Monday, May 11, 2026

5:30am - 6:30am PDT

Inhibrx Biosciences Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer

Tuesday, April 21, 2026

1:30pm - 2:30pm PDT

View All Events »

Stock Information

No ticker symbol specified

Investor Contact

Amy Conrad

Juniper Point

amy@juniper-point.com

858-366-3243